Kura Oncology, Inc. (NASDAQ:KURA) Stock Has Average Price Target of $25.69

Key Points

• Analyst sentiment is moderately bullish: 11 of 13 analysts rate Kura Oncology a buy, while one rates it a hold and one a sell. The average 12-month price target is $25.69 versus the stock’s reported $10.60 price.
• Insider activity was mixed: CEO Troy Wilson bought 100,000 shares for approximately $1.1 million, while insiders sold 153,881 shares worth about $1.7 million over the past 90 days.
• Kura reported a quarterly loss of $0.77 per share, beating estimates of a $0.88 loss, and revenue of $20.87 million. The biopharmaceutical company is focused on precision cancer medicines, including its lead menin inhibitor ziftomenib for genetically defined acute myeloid leukemia.

Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the thirteen research firms that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and eleven have issued a buy recommendation on the company. The average 1 year target price among brokers that have covered the stock in the last year is $25.69.

Several research firms have issued reports on KURA. Citizens Jmp restated a "market outperform" rating and set a $24.00 price objective on shares of Kura Oncology in a report on Monday, August 24th. JPMorgan Chase & Co. assumed coverage on shares of Kura Oncology in a report on Thursday, October 1st. They issued an "overweight" rating and a $30.00 target price for the company. UBS Group reissued a "buy" rating on shares of Kura Oncology in a research report on Monday, October 5th. Weiss Ratings restated a "sell (d-)" rating on shares of Kura Oncology in a report on Friday, July 17th. Finally, Wedbush upped their price target on shares of Kura Oncology from $36.00 to $38.00 and gave the company an "outperform" rating in a research report on Thursday, August 13th.

Insider Activity

In other news, CEO Troy Wilson bought 100,000 shares of the business's stock in a transaction on Monday, August 17th. The shares were bought at an average cost of $11.12 per share, with a total value of $1,112,000.00. Following the purchase, the chief executive officer directly owned 379,194 shares in the company, valued at $4,216,637.28. This trade represents a 35.82% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Brian Powl sold 17,020 shares of the business's stock in a transaction on Monday, September 28th. The shares were sold at an average price of $10.53, for a total transaction of $179,220.60. Following the sale, the insider directly owned 152,249 shares in the company, valued at approximately $1,603,181.97. This trade represents a 10.06% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 153,881 shares of company stock worth $1,708,183. 7.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Kura Oncology

Several institutional investors and hedge funds have recently bought and sold shares of the business. Tidal Investments LLC acquired a new position in shares of Kura Oncology in the second quarter worth $1,029,000. WINTON GROUP Ltd raised its holdings in shares of Kura Oncology by 26.2% during the second quarter. WINTON GROUP Ltd now owns 13,000 shares of the company's stock worth $143,000 after acquiring an additional 2,700 shares in the last quarter. Integrated Wealth Concepts LLC acquired a new stake in Kura Oncology during the second quarter valued at $159,000. IFP Advisors Inc boosted its position in Kura Oncology by 136.5% during the second quarter. IFP Advisors Inc now owns 2,542 shares of the company's stock valued at $28,000 after purchasing an additional 1,467 shares during the last quarter. Finally, Allworth Financial LP grew its stake in Kura Oncology by 148.4% in the second quarter. Allworth Financial LP now owns 10,326 shares of the company's stock valued at $113,000 after purchasing an additional 6,169 shares in the last quarter.

Kura Oncology Stock Performance

KURA opened at $10.60 on Friday. The company has a quick ratio of 4.71, a current ratio of 4.73 and a debt-to-equity ratio of 0.12. The firm has a market cap of $942.98 million, a PE ratio of -3.15 and a beta of 0.47. The business has a fifty day simple moving average of $11.36 and a 200-day simple moving average of $10.27. Kura Oncology has a fifty-two week low of $7.36 and a fifty-two week high of $13.90.

Kura Oncology (NASDAQ:KURA - Get Free Report) last announced its earnings results on Wednesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.88) by $0.11. Kura Oncology had a negative return on equity of 207.18% and a negative net margin of 384.30%. The company had revenue of $20.87 million for the quarter, compared to analyst estimates of $20.16 million. As a group, equities analysts predict that Kura Oncology will post -3.25 EPS for the current fiscal year.

About Kura Oncology

Kura Oncology, Inc is a biopharmaceutical company focused on developing precision medicines for the treatment of cancer. The company uses molecular and genomic insights to identify therapies designed to target specific biological drivers of tumor growth.

Kura's lead program is ziftomenib, an oral menin inhibitor developed for genetically defined forms of acute myeloid leukemia, including disease associated with NPM1 mutations and KMT2A rearrangements. The company has also evaluated additional targeted oncology candidates, including therapies directed at the RAF-MEK-ERK signaling pathway.

Founded in 2014 and headquartered in San Diego, California, Kura has conducted clinical development activities through research collaborations and studies involving patients and institutions in the United States and other regions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.